Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2009

Open Access 01-12-2009 | Research article

Expression of matrix metalloproteinases (MMPs) in primary human breast cancer and breast cancer cell lines: New findings and review of the literature

Authors: Andrea Köhrmann, Ulrike Kammerer, Michaela Kapp, Johannes Dietl, Jelena Anacker

Published in: BMC Cancer | Issue 1/2009

Login to get access

Abstract

Background

Matrix metalloproteinases (MMPs) are a family of structural and functional related endopeptidases. They play a crucial role in tumor invasion and building of metastatic formations because of their ability to degrade extracellular matrix proteins. Under physiological conditions their activity is precisely regulated in order to prevent tissue disruption. This physiological balance seems to be disrupted in cancer making tumor cells capable of invading the tissue. In breast cancer different expression levels of several MMPs have been found.

Methods

To fill the gap in our knowledge about MMP expression in breast cancer, we analyzed the expression of all known human MMPs in a panel of twenty-five tissue samples (five normal breast tissues, ten grade 2 (G2) and ten grade 3 (G3) breast cancer tissues). As we found different expression levels for several MMPs in normal breast and breast cancer tissue as well as depending on tumor grade, we additionally analyzed the expression of MMPs in four breast cancer cell lines (MCF-7, MDA-MB-468, BT 20, ZR 75/1) commonly used in research. The results could thus be used as model for further studies on human breast cancer. Expression analysis was performed on mRNA and protein level using semiquantitative RT-PCR, Western blot, immunohistochemistry and immunocytochemistry.

Results

In summary, we identified several MMPs (MMP-1, -2, -8, -9, -10, -11, -12, -13, -15, -19, -23, -24, -27 and -28) with a stronger expression in breast cancer tissue compared to normal breast tissue. Of those, expression of MMP-8, -10, -12 and -27 is related to tumor grade since it is higher in analyzed G3 compared to G2 tissue samples. In contrast, MMP-7 and MMP-27 mRNA showed a weaker expression in tumor samples compared to healthy tissue. In addition, we demonstrated that the four breast cancer cell lines examined, are constitutively expressing a wide variety of MMPs. Of those, MDA-MB-468 showed the strongest mRNA and protein expression for most of the MMPs analyzed.

Conclusion

MMP-1, -2, -8, -9, -10, -11, -12, -13, -15, -19, -23, -24, -27 and -28 might thus be associated with breast cancer development and tumor progression. Therefore, these MMPs are proper candidates for further functional analysis of their role in breast cancer.
Appendix
Available only for authorised users
Literature
1.
Tyczynski JE, Bray F, Parkin DM: Breast cancer in Europe. ENCR Cancer Fact Sheets. 2002, 2-
2.
Nagase H, Visse R, Murphy G: Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res. 2006, 69 (3): 562-73. 10.1016/j.cardiores.2005.12.002.CrossRefPubMed
3.
Page-McCaw A, Ewald AJ, Werb Z: Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol. 2007, 8: 211-233. 10.1038/nrm2125.CrossRef
4.
Stamenkovic I: Matrix metalloproteinases in tumor invasion and metastasis. Semin Cancer Biol. 2000, 10: 415-433. 10.1006/scbi.2000.0379.CrossRefPubMed
5.
Garbett EA, Reed MWR, Stephenson TJ, Brown NJ: Proteolysis in human breast cancer. J Clin Pathol, Mol Pathol. 2000, 53: 99-106. 10.1136/mp.53.2.99.CrossRef
6.
Curran S, Dundas SR, Buxton J, Leeman MF, Ramsay R, Murray GI: Matrix metalloproteinase/tissue inhibitors of matrix metalloproteinase phenotype identifies poor prognosis colorectal cancers. Clin Cancer Res. 2004, 10: 8229-8234. 10.1158/1078-0432.CCR-04-0424.CrossRefPubMed
7.
Forget MA, Desrosiers RR, Beliveau R: Physiological roles of matrix metalloproteinases: implications for tumor growth and metastasis. Can J Physiol Pharm. 1999, 77: 465-480. 10.1139/cjpp-77-7-465.CrossRef
8.
Duffy MJ, Maguire TM, Hill A, McDermott E, O'Higgins N: Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res. 2000, 2 (4): 252-7. 10.1186/bcr65.CrossRefPubMedPubMedCentral
9.
Gimbernardi TA, Grant GM, Taylor GP, Hay RJ, Maher VM, Mc Cormick JJ, Klebe RJ: Overview of matrix metalloproteinase expression in cultured human cells. Matrix Biol. 1998, 16: 483-96. 10.1016/S0945-053X(98)90019-1.CrossRef
10.
Iwasaki M, Nishikawa A, Fujimoto T, Akutagawa N, Manase K, Endo T, Yoshida K, Maekawa R, Yoshioka T, Kudo R: Anti-invasive Effect of MMI-166 New Selective Matrix Metalloproteinase Inhibitor, in Cervical Carcinoma Cell Lines. Gynecol Oncol. 2002, 85: 103-107. 10.1006/gyno.2001.6573.CrossRefPubMed
11.
Kato Y, Yamashita T, Ishikawa M: Relationship between expression of matrix metalloproteinase-2 and matrix metalloproteinase-9 and invasion ability of cervical cancer cells. Oncol Rep. 2002, 9: 565-569.PubMed
12.
Talvensaari-Mattila A, Pääkkö P, Höyhtyä M, Blanco-Sequeiros G, Turppnniemi Hujanen T: Matrix metalloproteinase-2 immunoreactive protein: a marker of aggressiveness in breast carcinoma. Cancer. 1998, 83: 1153-62. 10.1002/(SICI)1097-0142(19980915)83:6<1153::AID-CNCR14>3.0.CO;2-4.CrossRefPubMed
13.
Li HC, Cao DC, Liu Y, Hou YF, Wu J, Lu JS, Di GH, Liu G, Li FM, Ou ZL, Jie C, Shen ZZ, Shao ZM: Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in patients with lymph node-negative breast carcinoma. Breast Cancer Res Treat. 2004, 88: 75-85. 10.1007/s10549-004-1200-8.CrossRefPubMed
14.
Mitropoulou TN, Tzanakakis GN, Kletsas D, Kalofonos HP, Karamanos NK: Letrozole as a potent inhibitor of cell proliferation and expression of metalloproteinases (MMP-2 and MMP-9) by human epithelial breast cancer cells. Int J Cancer. 2003, 104 (2): 155-60. 10.1002/ijc.10941.CrossRefPubMed
15.
Vizoso FJ, Gonzales LO, Corte MD, Rodriguez JC, Vazquez J, Lamelas ML, Junquera S, Merino AM, Garcia-Muniz JL: Study of matrix metalloproteinases and their inhibitors in breast cancer. Br J Cancer. 2007, 96: 903-911. 10.1038/sj.bjc.6603666.CrossRefPubMedPubMedCentral
16.
Kossakowska AE, Huchcroft SA, Urbanski SJ, Edwards DR: Comparative analysis of the expression patterns of metalloproteinases and their inhibitors in breast neoplasia, sporadic colorectal neoplasia, pulmonary carcinomas and malignant non-Hodgkin's lymphomas in humans. Br J Cancer. 1996, 73: 1401-CrossRefPubMedPubMedCentral
17.
Decock J, Hendrickx W, Frijkoningen M, Wildiers H, Neven P, Smeets A, Paridaens R: Matrix metalloproteinase expression patterns in luminal A type breast carcinoma. Dis Markers. 2007, 23: 189-96.CrossRefPubMedPubMedCentral
18.
Gonzalez LO, Corte MD, Vazquez J, Junquera S, Sanchez R, Alvarez AC, Rodriguez JC, Lamelas ML, Visoso FJ: Androgen receptor expression in breast cancer: Relationship with clinicopathological characteristics of the tumors, prognosis, and expression of metalloproteases and their inhibitors. BMC Cancer. 2008, 8: 149-10.1186/1471-2407-8-149.CrossRefPubMedPubMedCentral
19.
Pacheco MM, Mourao M, Mantovani EB, Nishimoto IN, Brentani MM: Expression of gelatinases A and B, stromelysin-3 and matrilysin genes in breast carcinomas: clinico-pathological correlations. Clin Exp Metastasis. 1998, 16: 577-585. 10.1023/A:1006580415796.CrossRefPubMed
20.
Przybylowska K, Kluczna A, Zadrozny M, Krawczyk T, Kulig A, Rykala J, Kolacinska A, Morawiec Z, Drezewoski J, Blasiak J: Polymorphisms of the promoter regions of matrix metalloproteinases genes MMP-1 and MMP-9 in breast cancer. Breast Cancer Res Treat. 2006, 95: 65-72. 10.1007/s10549-005-9042-6.CrossRefPubMed
21.
Haupt LM, Irving RE, Weinstein SR, Irving MG, Griffiths LR: Matrix metalloproteinase localisation by in situ-RT-PCR in archival human breast biopsy material. Mol Cell Probes. 2008, 22 (2): 83-89. 10.1016/j.mcp.2007.06.009.CrossRefPubMed
22.
Ueno H, Nakamura H, Inoue M, Imai K, Noguchi M, Sato H, Seiki M, Okada Y: Expression and Tissue Localization of Membrane-Types 1, 2 and 3 Matrix Metalloproteinases in Human Invasive Breast Carcinomas. Cancer Res. 1997, 57: 2055-2060.PubMed
23.
Bartsch JE, Staren ED, Appert HE: Matrix Metalloproteinase Expression in Breast Cancer. J Surg Res. 2003, 11: 383-392. 10.1016/S0022-4804(03)00007-6.CrossRef
24.
Bachmeier BE, Nerlich AG, Lichtinghagen R, Sommerhoff CP: Matrix Metalloproteinases (MMPs) in Breast Cancer Cell Lines of Different Tumorigenicity. Anticancer Res. 2001, 21: 3821-3828.PubMed
25.
Stark AM, Anuszkiewicz B, Mentlein R, Yoneda T, Mehdorn HM, Held-Feindt J: Differential expression of matrix metalloproteinases in brain- and bone-seeking clones of metastatic MDA-MB-231 breast cancer cells. J Neurooncol. 2007, 81: 39-48. 10.1007/s11060-006-9207-0.CrossRefPubMed
26.
Haupt LM, Thompson EW, Trezise AE, Irving RE, Irving MG, Griffiths LR: In vitro and in vivo MMP gene expression localisation by In Situ-RT-PCR in cell culture and paraffin embedded human breast cancer cell line xenografts. BMC Cancer. 2006, 6: 18-10.1186/1471-2407-6-18.CrossRefPubMedPubMedCentral
27.
Balduyck M, Zerimech F, Gouyer V, Lemaire R, Hemon B, Grard G, Thiebaut C, Lemaire V, Dacquembronne E, Duhem T, Lebrun A, Dejonghe MJ, Huet G: Specific expression of matrix metalloproteinases 1, 3, 9 and 13 associated with invasiveness of breast cancer cells in vitro. Clin Exp Metastasis. 2000, 18: 171-178. 10.1023/A:1006762425323.CrossRefPubMed
28.
29.
Thompson EW, Paik S, Brunner N, Sommers CL, Zugmaier G, Clarke R, Shima TB, Torri J, Donahue S, Lippman ME: Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines. J Cell Physiol. 1992, 150: 534-544. 10.1002/jcp.1041500314.CrossRefPubMed
30.
Shafie SM, Liotta LA: Formation of metastasis by human breast carcinoma cells (MCF-7) in nude mice. Cancer Lett. 1980, 11: 81-87. 10.1016/0304-3835(80)90097-X.CrossRefPubMed
31.
Mukhopadhyay R, Theriault RL, Price JE: Increased levels of alpha6 integrins are associated with the metastatic phenotype of human breast cancer cells. Clin Exp Metastasis. 1999, 17: 325-332. 10.1023/A:1006659230585.CrossRefPubMed
32.
Sheikh MS, Shao ZM, Hussain A, Fontana J: The p53-binding protein MDM2 gene is differentially expressed in human breast carcinoma. Cancer Res. 1993, 53: 3226-3228.PubMed
33.
Maemura M, Akiyama SK, Woods VLJ, Dickson RB: Expression and ligand binding of alpha 2 beta 1 integrin on breast carcinoma cells. Clin Exp Metastasis. 1995, 13: 223-235. 10.1007/BF00133478.CrossRefPubMed
34.
Hall RE, Lee CS, Alexander IE, Shine J, Clarke CL, Sutherland RL: Steroid hormone receptor gene expression in human breast cancer cells: inverse relationship between oestrogen and glucocorticoid receptor messenger RNA levels. Int J Cancer. 1990, 46: 1081-1087. 10.1002/ijc.2910460622.CrossRefPubMed
35.
Tong D, Czerwenka K, Sedlak J, Schneeberger C, Schiebel I, Concin N, Leodolter S, Zeillinger R: Association of in vitro invasiveness and gene expression of estrogen receptor, progesterone receptor, pS2 and plasminogen activator inhibitor-1 in human breast cancer cell lines. Breast Cancer Res Treat. 1999, 56: 91-97. 10.1023/A:1006262501062.CrossRefPubMed
36.
Thompson EW, Paik S, Brünner N, Sommers CL, Zugmaier G, Clarke R, Shima TB, Torri J, Donahue S, Lippman ME, et al: Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines. J Cell Physiol. 1992, 150 (3): 534-544. 10.1002/jcp.1041500314.CrossRefPubMed
37.
Janssens N, Janicot M, Perera T, Bakker A: Housekeeping genes as internal standards in cancer research. Mol Diagn. 2004, 8 (2): 107-113. 10.2165/00066982-200408020-00005.CrossRefPubMed
38.
Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976, 72: 248-54. 10.1016/0003-2697(76)90527-3.CrossRefPubMed
39.
40.
Saez RA, McGuire WL, Clark GM: Progonstic factors in breast cancer. Semin Surg Onco. 1989, 52: 5198-5203.
41.
Iwata H, Kobayashi S, Iwase H, Masaoka A, Fujimoto N, Okada Y: Production of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human breast carcinomas. Jpn J Cancer Res. 1996, 87: 602-611.CrossRefPubMed
42.
Heppner KJ, Matrisian LM, Jensen RA, Rodgers WH: Expression of most matrix metalloproteinase family members in breast cancer represents a tumor induced host response. Am J Pathol. 1996, 149: 273-282.PubMedPubMedCentral
43.
Gutiérrez-Fernández A, Fueyo A, Folgueras AR, Garabaya C, Pennington CJ, Pilgrim S, Edwards DR, Holliday DL, Jones JL, Span PN, Sweep FC, Puente XS, López-Otín C: Matrix metalloproteinase-8 functions as metastasis suppressor through modulation of tumor cell adhesion and invasion. Cancer Res. 2008, 68 (8): 2755-63. 10.1158/0008-5472.CAN-07-5154.CrossRefPubMed
44.
Duffy MJ, Blaser J, Duggan C, McDermott E, O'Higgins N, Fennelly JJ, Tschesche H: Assay of matrix metalloproteinase type 8 and 9 by ELISA in human breast cancer. Br J Cancer. 1995, 71: 1025-8.CrossRefPubMedPubMedCentral
45.
Zhang B, Cao X, Liu Y, Cao W, Zhang F, Zhang S, Li H, Ning L, Fu L, Niu Y, Niu R, Sun B, Hao X: Tumor-derived matrix metalloproteinase-13 (MMP-13) correlates with poor Prognoses of invasive breast cancer. BMC Cancer. 2008, 8: 83-10.1186/1471-2407-8-83.CrossRefPubMedPubMedCentral
46.
Talvensaari-Mattila A, Pääkkö P, Blanco-Sequeiro G, Turpeenniemi-Hujanen T: Matrix metalloproteinase-2 (MMP2) is associated with the risk for a relapse in postmenopausal patients with node-positive breast carcinoma treated with antiestrogen adjuvant therapy. Breast Cancer Res Treat. 2001, 65: 55-61. 10.1023/A:1006458601568.CrossRefPubMed
47.
Jones JL, Glynn P, Walker RA: Expression of MMP-2 and MMP-9, their inhibitors and the activator MT1-MMP in primary breast carcinomas. J Pathol. 1999, 189: 161-168. 10.1002/(SICI)1096-9896(199910)189:2<161::AID-PATH406>3.0.CO;2-2.CrossRefPubMed
48.
Rhako E, Jukkola A, Melkko J: Matrix metalloproteinase-9 (MMP-9) immunoreactive protein has modest prognostic value in locally advanced breast carcinoma patients treated with an adjuvant antiestrogen therapy. Anticancer Res. 2004, 24: 4247-4254.
49.
Ip YC, Cheung ST, Fan ST: Atypical localization of membrane type 1-matrix metalloproteinase in the nucleus is associated with aggressive features of hepatocellular carcinoma. Mol Carcinog. 2007, 46 (3): 225-30. 10.1002/mc.20270.CrossRefPubMed
50.
Lengyel E, Schmalfeldt B, Konik E, Späthe K, Härting K, Fenn A, Berger U, Fridman R, Schmitt M, Prechtel D, Kuhn W: Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer. Gynecol Oncol. 2001, 82 (2): 291-8. 10.1006/gyno.2001.6243.CrossRefPubMed
51.
Djonov V, Hogger K, Sedlacek R, Laissue J, Draeger A: MMP-19: cellular localization of a novel metalloproteinase within normal breast tissue and mammary gland tumors. J Pathol. 2001, 195: 147-155. 10.1002/path.927.CrossRefPubMed
52.
Sternlicht MD, Werb Z: How matrix metalloproteinases regulate cell behaviour. Annu Rev Cell Dev Biol. 2001, 17: 463-516. 10.1146/annurev.cellbio.17.1.463.CrossRefPubMedPubMedCentral
53.
Savinov AY, Remacle AG, Golubkov VS, Krajewska M, Kennedy S, Duffy MJ, Rozanov DV, Krajewski S, Strongin AY: Matrix metalloproteinase 26 proteolysis of the NH2-terminal domain of the estrogen receptor beta correlates with the survival of breast cancer patients. Cancer Res. 2006, 66 (5): 2716-24. 10.1158/0008-5472.CAN-05-3592.CrossRefPubMed
54.
Grant GM, Gimbernardi TA, Grant AM, Klebe RJ: Overview of expression of matrix metalloproteinases (MMP-17, MMP-18, and MMP-20) in cultured human cells. Matrix Biol. 1999, 18: 145-148. 10.1016/S0945-053X(99)00003-7.CrossRefPubMed
55.
Kousidou OC, Roussidis AE, Theocharis AD, Karamanos NK: Expression of MMPs and TIMPs genes in human breast cancer epithelial cells depends on cell culture conditions and is associated with their invasive potential. Anticancer Res. 2004, 24 (6): 4025-30.PubMed
56.
Vihinen P, Kahari VM: Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer. 2002, 99: 157-166. 10.1002/ijc.10329.CrossRefPubMed
Metadata
Title
Expression of matrix metalloproteinases (MMPs) in primary human breast cancer and breast cancer cell lines: New findings and review of the literature
Authors
Andrea Köhrmann
Ulrike Kammerer
Michaela Kapp
Johannes Dietl
Jelena Anacker
Publication date
01-12-2009
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2009
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-9-188

Other articles of this Issue 1/2009

BMC Cancer 1/2009 Go to the issue

Research article

Activity of mevalonate pathway inhibitors against breast and ovarian cancers in the ATP-based tumour chemosensitivity assay

Research article

ST3Gal.I sialyltransferase relevance in bladder cancer tissues and cell lines

Research article

Sensitive HPV detection in oropharyngeal cancers

Research article

Wnt pathway reprogramming during human embryonal carcinoma differentiation and potential for therapeutic targeting

Research article

Vasohibin inhibits angiogenic sprouting in vitro and supports vascular maturation processes in vivo

Research article

Assessing pathogenicity of MLH1 variants by co-expression of human MLH1 and PMS2genes in yeast
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits